FDA Approval of Adjuvant Pembrolizumab for NSCLC | IASLC

On January 26, 2023, the US FDA granted approval for pembrolizumab, an anti-PD-1 antibody, as adjuvant therapy for patients with resected NSCLC. In this episode …

Read the full article here

Related Articles